Study of Acetyllevocarnitine Hydrochloride Tablets in Chinese Patients With Paresthesias Caused by DPN

Inclusion Criteria: * Age ≥ 18 and ≤ 70 years, Male and female patients; * Type 1 or 2 diabetes mellitus on hypoglycemic therapy for 3 months or more, and clinical diagnosis of DPN; * HbA1c \< 9.0%; * Toronto Clinical Neuropathy Score ≥ 6 at screening and baseline. Exclusion Criteria: * Peripheral neuropathy caused by other diseases; * History of acute complications of diabetes within the past 6 months, such as diabetic ketoacidosis, diabetic hyperosmolar hyperglycemia syndrome or lactic acidosis, etc.; * Severe peripheral arterial disease; severe cardiopulmonary disease; or have a history of myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months before enrollment; or uncontrolled asthma or shortness of breath 2 months before enrollment; World Health Organization (WHO) cardiac function class III-IV; systolic blood pressure \>160 mmHg or diastolic blood pressure \>90 mmHg at screening; * Any infection at the screening visit that is not suitable for study participation; * Aspartate Transaminase (AST) or Alanine Transaminase (ALT) or total bilirubin or creatinine \> 2 times Upper Limit of Normal (ULN); * Known allergy to L-carnitine ingredients; * Severe systemic or psychiatric illness, history of epilepsy; * History of malignancy or antitumor therapy; * Severe bleeding disorder; * Clinically significant abnormalities in thyroid function tests; * Triglyceride \>5.6 mmol/L; * Change of 2 points or more in the same item in mTCNS; * Nursing or pregnant women.